Curis | CRIS - Gross Profit On Sales


Curis reported $-7.72M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bayer EUR 5.35B 1.02B Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
CSL USD 4.46B 2.71B Dec/2025
Curis USD -7.72M 140K Jun/2024
Eli Lilly USD 14.59B 1.48B Sep/2025
Exelixis USD 572.18M 7M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.25B 570M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Verastem USD 545K 543K Dec/2021
Xoma 992K 846K Jun/2024